LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. - Masip, J. Remon; Besse, B.; Aix, S. Ponce; Callejo, A.; Al-Rabi, K.; Caro, R. Bernabe; Greillier, L.; Tarruella, M. Majem; Aransay, N. Reguart; Monnet, I.; Cousin, S.; Lopez, P. Garrido; et al. (Annals of Oncology, 2022)